$588 Million is the total value of BVF INC/IL's 30 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ANAB | New | ANAPTYSBIO INC | $48,246,000 | – | 1,738,600 | +100.0% | 8.21% | – |
CTIC | New | CTI BIOPHARMA CORP | $18,815,000 | – | 4,479,691 | +100.0% | 3.20% | – |
BLRX | New | BIOLINERX LTD SPONSOREDsponsored adr | $16,809,000 | – | 17,500,000 | +100.0% | 2.86% | – |
LOXO | New | LOXO ONCOLOGY INC | $13,466,000 | – | 320,000 | +100.0% | 2.29% | – |
RGLS | New | REGULUS THERAPEUTICS INC | $1,028,000 | – | 623,000 | +100.0% | 0.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
ARQULE INC | 27 | Q4 2019 | 4.8% |
CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-01-29 |
3 | 2024-01-26 |
4 | 2024-01-09 |
4 | 2023-12-20 |
4 | 2023-11-17 |
13F-HR | 2023-11-14 |
3 | 2023-11-13 |
3 | 2023-11-06 |
4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.